Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the ...

On Monday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $26.24 which represents a slight increase of $0.01 or 0.04% from the prior close of $26.23. The stock opened at $26.23 and ...

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

On Wednesday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $29.35 which represents a slight increase of $0.85 or 2.98% from the prior close of $28.5. The stock opened at $28.7 and ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

Exelixis (EXEL) stock surged 7.3% after winning a patent battle against generic drug maker MSN Laboratories over Cabometyx.

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $30.00 to ...

A court ruled in favor of Exelixis in the oncology company's patent-infringement lawsuit against MSN Laboratories.